Literature DB >> 1369023

"Primatization" of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against human CD4.

R Newman1, J Alberts, D Anderson, K Carner, C Heard, F Norton, R Raab, M Reff, S Shuey, N Hanna.   

Abstract

Immunoglobulin variable region genes from non-human primates, cynomolgus macaques, were shown to have 85%-98% homology with human immunoglobulin sequences and yet macaques are phylogenetically distant enough to respond against conserved human antigens. Immunoglobulin genes were isolated from monkeys immunized with human CD4 antigen and a human/monkey chimeric anti-CD4 antibody with 91-92% homology to human immunoglobulin framework regions was cloned and expressed. The antibody has an apparent affinity of 3.2 x 10(-11) M and exhibits potent immunosuppressive properties in vitro.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1369023     DOI： 10.1038/nbt1192-1455

Source DB:  PubMed          Journal:  Biotechnology (N Y)        ISSN： 0733-222X


  13 in total

1.  Immunoglobulin V(H) usage during primary infection of rhesus monkeys with chimeric simian-human immunodeficiency viruses.

Authors:  D H Margolin; K A Reimann; J Sodroski; G B Karlsson; K Tenner-Racz; P Racz; N L Letvin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694.

Authors:  Emmanuelle Laffly; Ludivine Danjou; Florence Condemine; Dominique Vidal; Emmanuel Drouet; Marie-Paule Lefranc; Chantal Bottex; Philippe Thullier
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Analysis of the expressed heavy chain variable-region genes of Macaca fascicularis and isolation of monoclonal antibodies specific for the Ebola virus' soluble glycoprotein.

Authors:  Chris Druar; Surinder S Saini; Meredith A Cossitt; Fei Yu; Xiangguo Qiu; Thomas W Geisbert; Steven Jones; Peter B Jahrling; Donald I H Stewart; Erik J Wiersma
Journal:  Immunogenetics       Date:  2005-11-08       Impact factor: 2.846

4.  Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.

Authors:  T K Hart; M N Blackburn; M Brigham-Burke; K Dede; N Al-Mahdi; P Zia-Amirhosseini; R M Cook
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

Review 5.  Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance.

Authors:  Benjamin Bonavida
Journal:  Semin Oncol       Date:  2014-08-12       Impact factor: 4.929

6.  Stimulation of HIV-1-neutralizing antibodies in simian HIV-IIIB-infected macaques.

Authors:  S Müller; D H Margolin; P L Nara; W G Alvord; H Köhler
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

7.  Two neutralizing human anti-RSV antibodies: cloning, expression, and characterization.

Authors:  C Heard; P Brams; E Walsh; T Huynh; S Chamat; M Reff; A Owyang; W Shestowsky; R Newman
Journal:  Mol Med       Date:  1999-01       Impact factor: 6.354

8.  Inhibition of contact sensitivity in human CD4+ transgenic mice by human CD4-specific monoclonal antibodies: CD4+ T-cell depletion is not required.

Authors:  P L Podolin; E F Webb; M Reddy; A Truneh; D E Griswold
Journal:  Immunology       Date:  2000-02       Impact factor: 7.397

9.  High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation.

Authors:  Thibaut Pelat; Michael Hust; Emmanuelle Laffly; Florence Condemine; Chantal Bottex; Dominique Vidal; Marie-Paule Lefranc; Stefan Dübel; Philippe Thullier
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

10.  Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.

Authors:  C Y Kang; K Hariharan; P L Nara; J Sodroski; J P Moore
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.